Abstract:
The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.
Abstract:
The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
Abstract:
Provided are a multicomponent crystalline system (co-crystal), use thereof, as well as a process for obtaining the same. The said multicomponent crystalline system (co-crystal) comprises Dasatinib and a second compound selected from methyM-hydrobenzoate, nicotinamide, ethyl gallate, methyl gallate, propyl gallate, ethyl maltol, vanillin, menthol, or (1R,2S,5R)-(−)-menthol.
Abstract:
The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
Abstract:
The present invention relates to a process for edge-halogenation of a graphene material; wherein the graphene material, which is selected from graphene, a graphene nanoribbon, a graphene molecule, or a mixture thereof, is reacted with a halogen-donor compound in the presence of a Lewis acid, so as to obtain an edge-halogenated graphene material.
Abstract:
The present invention relates to a process for preparing a graphene nanoribbon, which comprises: (a) providing at least one aromatic monomer compound which is selected from at least one polycyclic aromatic monomer compound, at least one oligo phenylene aromatic monomer compound, or combinations thereof, on a solid substrate, (b) polymerization of the aromatic monomer compound so as to form at least one polymer on the surface of the solid substrate, (c) at least partially cyclodehydrogenating the one or more polymers of step (b), wherein at least step (b) is carried out at a total pressure p(total) of at least 1×10−9 mbar; and a partial oxygen pressure p(O2) and partial water pressure p(H2O) which satisfy the following relation: p(O2)×p(H20)
Abstract:
A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.
Abstract:
A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 independently of each other are for example hydrogen, halogen, C1-C20alkyl, C6-C14aryl which is unsubstituted or substituted; or R1, R2 and R3 and/or R4, R5 and R6 and/or R7, R8 and R9 and/or R10, R11 and R12 together with the C-atom to which they are attached each form a C6-C14aryl group which is unsubstituted or substituted; or R1 and R2 and/or R4 and R5 and/or R7 and R8 and/or R10 and R11 together with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (IIa), (IIb) or (IIc), wherein R1, R2, R3, R4, R5 and R6 are defined as above for formula (I), is suitable as a photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid.
Abstract:
In a process for purifying graphene nanoribbons, a composition comprising graphene nanoribbons GNR1 and at least one contaminant is brought into contact with a liquid medium that includes a dispersant. The graphene nanoribbons GNR1 are dispersed in the liquid medium so as to obtain a liquid dispersion of the graphene nanoribbons GNR1. The liquid dispersion of the graphene nanoribbons GNR1 is subjected to a separation treatment so as to at least partly remove the at least one contaminant, thereby obtaining a liquid dispersion of purified graphene nanoribbons GNR1.
Abstract:
Novel solid forms of imatinib mesilate comprising as active ingredient 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]-benzamide methanesulfonic acid salt and as co-crystal former benzoic acid, fumaric acid or succinic acid are described. The said multi-component crystalline forms possess improved physical and biological properties with respect to the crystalline forms of the active pharmaceutical ingredient previously known.